• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Delpor wins $1.5m NIH grant for diabetes drug implant

June 14, 2017 By Sarah Faulkner

DelporDelpor Inc. said today that it won a $1.5 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases to support the development of its exenatide implant.

The implant was designed for patients with Type II diabetes and features Delpor’s Nanopor technology, which uses passive diffusion to deliver therapeutic levels of exenatide for at least 3 months.

The 2-year grant includes $741,023 for the 1st year and $734,407 for the 2nd year, contingent upon availability of funds and the project’s progress.

“We are extremely grateful to the NIDDK for continuing to support us in the development of this very important and innovative product,” president & CEO Tassos Nicolaou said in prepared remarks. “DLP-414 will provide a safer, more efficacious, cost effective, and less invasive maintenance therapy for patients suffering from type 2 diabetes, and the further validation of the proposed technology will create the potential for a safer, and more convenient delivery of proteins and peptides.”

Exenatide, a glucagon-like peptide-1 receptor agonist, boosts glucose-dependent insulin secretion by the pancreatic beta-cell and lessens inappropriately-elevated glucagon secretion, according to Delpor.

“The aging and overweight patient population and rising healthcare costs, have shifted the industry focus from acute care, to cost effective chronic disease management,” Nicolaou added. “DLP-414 has the potential to extend the exenatide formulation for as long as 1 year, while offering full reversibility in case the patient has a treatment related adverse event.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news

Filed Under: Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Implants, Pharmaceuticals, Research & Development Tagged With: delpor, National Institutes of Health

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS